BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21680694)

  • 1. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.
    Hugonnet F; Fournier L; Medioni J; Smadja C; Hindié E; Huchet V; Itti E; Cuenod CA; Chatellier G; Oudard S; Faraggi M;
    J Nucl Med; 2011 Jul; 52(7):1048-55. PubMed ID: 21680694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
    Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
    Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
    Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
    Kayani I; Avril N; Bomanji J; Chowdhury S; Rockall A; Sahdev A; Nathan P; Wilson P; Shamash J; Sharpe K; Lim L; Dickson J; Ell P; Reynolds A; Powles T
    Clin Cancer Res; 2011 Sep; 17(18):6021-8. PubMed ID: 21742806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
    Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI
    Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
    Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
    Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
    Vercellino L; Bousquet G; Baillet G; Barré E; Mathieu O; Just PA; Desgrandchamps F; Misset JL; Hindié E; Moretti JL
    Cancer Biother Radiopharm; 2009 Feb; 24(1):137-44. PubMed ID: 19243256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
    Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
    Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.
    Haider MA; Vosough A; Khalvati F; Kiss A; Ganeshan B; Bjarnason GA
    Cancer Imaging; 2017 Jan; 17(1):4. PubMed ID: 28114978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
    Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
    Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
    Minamimoto R; Barkhodari A; Harshman L; Srinivas S; Quon A
    PLoS One; 2016; 11(4):e0153321. PubMed ID: 27123976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
    Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
    Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Late Recurrence a Predictive Clinical Marker for Better Sunitinib Response in Metastatic Renal Cell Carcinoma Patients?
    Bozkurt O; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Karaca H; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
    Clin Genitourin Cancer; 2015 Dec; 13(6):548-54. PubMed ID: 26320661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.
    Bex A; Blank C; Meinhardt W; van Tinteren H; Horenblas S; Haanen J
    Urology; 2011 Oct; 78(4):832-7. PubMed ID: 21802123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.